Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions

Area of Science:

• Endocrinology
• Pharmacology
• Diabetes Management

Background:

• Concentrated insulin products have existed since the 1950s but required complex dosing and patient education.
• Traditional concentrated insulins necessitated cumbersome dose conversions and detailed administration instructions.

Purpose of the Study:

• To highlight the differences between traditional and novel concentrated insulin products.
• To emphasize the importance of understanding new concentrated insulin formulations for safe clinical practice.
• To guide clinicians in selecting appropriate insulin products based on patient needs.

Main Methods:

• Review of available literature and product information on concentrated insulin formulations.
• Comparison of dosing procedures, administration methods, and clinical indications for traditional and novel concentrated insulins.
• Analysis of potential benefits and risks associated with new concentrated insulin products.

Main Results:

• Novel concentrated insulin products (introduced in 2015-2016) are exclusively available in pen devices with automatic dose conversion.
• These new products simplify administration, reduce the need for complex calculations, and may decrease the number of daily injections.
• Unlike older U-500 products, novel concentrated insulins are not solely indicated for severe insulin resistance.

Conclusions:

• Clinicians and patients must recognize the distinct features of novel concentrated insulins to prevent dosing errors.
• The new pen devices offer reduced complexity, fewer errors, and bypass the need for manual dose conversion.
• Appreciating the nuances among different concentrated insulin agents is imperative for optimal patient care and treatment selection.